CTOs on the Move

Meridian Heights Afc

www.hiawathabehavioral.org

 
Meridian Heights Afc is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Automated Group Administration

Automated Group Administration, Inc. is a Fort Wayne, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Danisco USA

Danisco Venture (www.danisco.com/venture) is a corporate venture unit within Danisco A/S - one of the world's largest producers of ingredients for the food and feed industry.

Collaborative Imaging

Collaborative Imaging is a radiologist owned alliance conceived by forward thinking physicians in conjunction with proven business experts to combat the growing threat of consolidation in radiology, degradation in patient care, physician burn-out, and operational inefficiencies plaguing radiologists, while providing a sustainable business model to allow its partners to realize additional revenue opportunities, all while retaining their full autonomy as an independent radiology practice.

Optimal Health Institute

Optimal Health Institute is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.